LLY LLY
Major Shareholder Sells Over $260 Million of Eli Lilly Stock
Lilly Endowment Inc., a major shareholder in Eli Lilly, sold 301,342 shares of the company's stock for a total value of approximately $260.16 million. The...
Eli Lilly Announces $3 Billion Investment in New Netherlands Manufacturing Facility
Eli Lilly and Company has announced plans to build a new $3 billion (€2.6 billion) manufacturing facility in Katwijk, the Netherlands. The site, located within...
HSBC Raises Eli Lilly Price Target to $850, Maintains Hold Rating
HSBC analysts adjusted their price target on Eli Lilly and Co. to $850 from $800, while maintaining their "Hold" rating on the company's shares. This change...
Eli Lilly Beats Q3 Estimates and Raises Full-Year Guidance on Strong Weight-Loss Drug Sales
Eli Lilly and Company announced third-quarter financial results that significantly surpassed Wall Street expectations, driven by surging demand for its...
Eli Lilly Announces $1.2 Billion Puerto Rico Manufacturing Expansion
On October 29, 2025, Eli Lilly announced a planned investment of more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in...
Eli Lilly Partners with Walmart to Offer Zepbound with Direct-to-Consumer Pricing at Retail Pharmacies
Eli Lilly and Company has announced a collaboration with Walmart to make its weight-loss drug, Zepbound, available for pick-up at Walmart pharmacies nationwide...
Eli Lilly Hosts Q3 Earnings Call Ahead of Highly Anticipated Financial Results
Eli Lilly and Company held its third-quarter 2025 earnings conference call with the investment community on October 29, 2025. The call took place ahead of the...
Eli Lilly Announces Partnership with NVIDIA for Industry-Leading AI Supercomputer
On October 28, 2025, Eli Lilly announced a major collaboration with NVIDIA to build the industry's most powerful AI supercomputer, aiming to accelerate drug...
Eli Lilly CEO Reveals Billions of Oral Weight-Loss Pills Already Produced Ahead of FDA Submission
Eli Lilly's CEO, Dave Ricks, announced that the company has already manufactured billions of doses of its next-generation oral weight-loss pill, orforglipron,...
Eli Lilly Declares Q4 2025 Dividend Amid Continued Growth Momentum
On October 27, 2025, Eli Lilly's board declared a fourth-quarter dividend of $1.50 per share, payable December 10, 2025 to shareholders of record as of...
Lilly Partners with Shaquille O'Neal to Raise Awareness for Sleep Apnea
On October 27, 2025, Eli Lilly announced a partnership with NBA legend Shaquille O'Neal to launch a nationwide campaign raising awareness about...
Eli Lilly's Omvoh Shows Early, Sustained Bowel Urgency Improvement in Ulcerative Colitis Patients
Eli Lilly and Company announced new positive data from its Phase 3b LUCENT-URGE study for Omvoh, a treatment for moderately to severely active ulcerative...
Eli Lilly Announces Acquisition of Adverum Biotechnologies
On October 24, 2025, Eli Lilly announced an agreement to acquire Adverum Biotechnologies, including its leading Ixo-vec gene therapy candidate. The deal...
Eli Lilly Reports Positive Results for EBGLYSS and Baricitinib in New Clinical Studies
On October 24, 2025, Eli Lilly announced new clinical results for EBGLYSS (lebrikizumab-lbkz), showing durable disease control in moderate-to-severe atopic...
Eli Lilly advances $5B U.S. manufacturing expansion amid tariff risks
On October 24, 2025, Eli Lilly's $5 billion investment in a new Virginia manufacturing facility was highlighted, marking the first of four planned U.S. sites....
Eli Lilly Partners with Cipla to Expand Access to Tirzepatide in India with Second Brand, Yurpeak®
Eli Lilly and Company has announced a strategic agreement with Indian pharmaceutical company Cipla to enhance the reach of its blockbuster drug, tirzepatide,...
Eli Lilly Acquires Verve Therapeutics, Entering Cardiovascular Gene-Editing Field
Eli Lilly and Company has announced its acquisition of Verve Therapeutics, a move that marks its entry into the field of gene-editing for cardiovascular...
Eli Lilly to Announce Third-Quarter 2025 Financial Results on October 30, 2025
Eli Lilly and Company has confirmed it will announce its third-quarter 2025 financial results on Thursday, October 30, 2025. The company will also hold a...
Eli Lilly Entrusts $25 Billion Retirement Portfolio to Goldman Sachs
Eli Lilly and Co. has decided to transfer the management of its $25 billion U.S. and Puerto Rican retirement assets to Goldman Sachs. This move, reported on...
Eli Lilly Shares Decline Following Trump's Remarks on Weight-Loss Drug Pricing
Eli Lilly and Company (LLY) shares experienced a significant drop of over 4% in premarket trading on Friday, October 17, 2025. The decline followed comments...